Hepatitis C Clinical Trial
Official title:
The Effect of Aerobic Exercise on Liver Enzymes in Overweight Prediabetic Patients With Hepatitis c
Exercise is one of the most vital components of health maintenance. Exercising regularly
maintains the cardiovascular system health, promotes the health of liver, and declines the
risks of complications induced by CHCV. Since overweight is the main risk factor for IR and
type 2 DM which may speed the liver disease progression among HCV patients, exercise is very
important for maintenance and loss of weight. Further, exercise can relieve the side effects
of medications of HCV, improve immunity, promote a sense of well-being, reduce levels of
chronic fatigue, improve blood oxygen levels and increase the endorphins excretion which
makes the patients fully energized (Elgendi, Shebl A, Sliem M, and Gary FA, 2018).
Studies on exercise effect in patients with CHCV are quite scarce (de Sousa Fernandes et al.,
2019). Decreased leptin levels by exercise positively modulate insulin signaling and inhibit
pathology progression (Anaruma et al., 2019). Since studies investigated physical activity
effect on regulating HCV related leptin levels are very little, the present study aimed to
explore the response of serum leptin and liver enzymes to aerobic exercise in nondiabetic
overweight men with CHCV.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | March 2021 |
Est. primary completion date | January 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Men with hepatitis C patients at least from 6 months - BMI ranged = 25 to < 30 kg/m2. - fasting blood glucose level (FBG) < 100 mg/dl. - waist circumference < 102 cm. Exclusion Criteria: - Besides the excluded individuals who participated in any form of physical training in the last 6 months, excluded patients by a physician will be patients with acute or other hepatitis types, cirrhotic or hepatocellular carcinoma, renal or respiratory problems, cardiovascular and neurologic diseases, and hypertension |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of Physical Therapy Cairo University | Giza | Dokki |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Leptin | It will be measured in plasma | It will be after 12-week training | |
Primary | Liver enzymes | Serum alanine and aspartate transaminases (AST), (ALT) will be measured in plasma | liver enzymes will be after 12-week training | |
Secondary | weight | With an empty bladder and stomach, weight will be measured for every participant | It will be after 12-week training | |
Secondary | Waist circumference (WC) | WC will be measured with an inelastic tape at the umbilicus level | It will be after 12-week training | |
Secondary | fasting blood glucose (FBG) | FBG will be measured by On Call ® Plus Acon, REF G113- 214, made in China | It will be after 12-week training |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 |